MedPath

Monitoring Drug-induced Myocarditis (CardiTOX)

Completed
Conditions
Myocardial Dysfunction
Myocarditis
Myocardial Failure
Interventions
Drug: Drug inducing myocarditis
Registration Number
NCT03855982
Lead Sponsor
Groupe Hospitalier Pitie-Salpetriere
Brief Summary

Several drugs and chemotherapies seem to induce myocarditis. This study investigates reports of myocarditis, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Detailed Description

Several drugs and chemotherapies seem to have an impact on the myocardium and are responsible of myocarditis. Those are poorly described, due to the modification of the pharmacopeia, and the recent recognition of several of these adverse events. This study investigates the main characteristics of patients affected by myocarditis side effect imputed to drugs. A causality assessment according to the WHO-UMC (World Health Organization - Uppsala Monitoring Center) is systematically applied.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6000
Inclusion Criteria
  • Case reported in the WHO's pharmacovigilance database till 25/02/2019
Exclusion Criteria
  • Chronology not compatible between the drug and the toxicity

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
myocarditis induced by drugs and chemotherapiesDrug inducing myocarditisCase reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
Primary Outcome Measures
NameTimeMethod
Number of myocarditis induced by drugs and report of cases of myocarditis associated with drugs.Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019
Secondary Outcome Measures
NameTimeMethod
Causality assessment of reported myocarditis events according to the WHO systemCase reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019
Description of the myocarditis depending on the category of drugCase reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019
Description of the other related adverse events concomitant to the myocarditis induced by drugsCase reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019
Description of the duration of treatment when the toxicity happens (role of cumulative dose)Case reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019
Description of the drug-drug interactions associated with adverse eventsCase reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019
Description of the population of patients having myocarditis adverse eventCase reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019
Description of the pathologies (cancer) for which the incriminated drugs have been prescribedCase reported in the World Health Organization (WHO) database of individual safety case reports to 25/02/2019

Trial Locations

Locations (1)

AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath